Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy

BCR-ABL inhibitors administered in conjunction with chemotherapy have significantly improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia but, for patients diagnosed during pregnancy, data on risks to the fetus are limited. We report a woman treated with chemotherapy and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2016-04, Vol.22 (2), p.374-377
Main Authors: Mainor, Candace B, Duffy, Alison P, Atkins, Kristin L, Kimball, Amy S, Baer, Maria R
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Female
Humans
Imatinib Mesylate - therapeutic use
Infant, Newborn
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Pregnancy
Pregnancy Complications, Neoplastic - diagnosis
Pregnancy Complications, Neoplastic - drug therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BCR-ABL inhibitors administered in conjunction with chemotherapy have significantly improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia but, for patients diagnosed during pregnancy, data on risks to the fetus are limited. We report a woman treated with chemotherapy and imatinib mesylate who delivered a healthy baby at 30 weeks, and we discuss available data.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155214568582